从归母净利润增速来看，6家企业实现同比增长超100%。8月23日，科兴生物制药股份有限公司公告 称，公司2025年上半年归母净利润实现8034.45万元，同比增长576.45%，成为行业"增速王"；成都圣诺 生物科技股份有限公司（以下简称"圣诺生物"）以308.29%的同比增速位居行业第二；金凯（辽宁）生 命科技股份有限公司（以下简称"金凯生科"）以123.61%的同比增速，位居行业第三。 当前，上市公司2025年半年报正在密集披露中，多家创新药企在营收、归母净利润等核心指标上表现亮 眼，行业整体展现良好发展态势。Wind数据显示，截至8月24日，共计39家创新药企发布2025年半年度 业绩报告，其中27家归母净利润变动幅度实现正增长，占比达69.23%，更有6家企业归母净利润同比增 长超100%。 盘古智库高级研究员江瀚表示，通过这一成绩单可以看出行业已经走出了低谷期，盈利动能显著恢复。 从周期位置判断，利润增长开始兑现，标志着行业正从"投入期"迈入"收获期"，整体进入温和扩张阶 段，景气度处于回升通道。 6家净利同比增长超100% 从营收规模来看，3家企业位处"百亿元梯队"。华东医药股份有限公司（以下简称 ...

Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2025, with total revenue reaching 2.067 billion yuan, a year-on-year growth of 57.18%, and net profit attributable to shareholders at 604 million yuan, up 101.96% [1] - Domestic business revenue was 1.845 billion yuan, while international business revenue was 222 million yuan, indicating strong performance in both markets [1] Domestic Market Performance - Domestic sales revenue increased by 655 million yuan compared to the same period last year, reflecting a growth of 55.28% [1] - The sales revenue from domestic formulations reached 1.802 billion yuan, marking a 57.09% increase year-on-year [1] - The company successfully expanded its market share through two rounds of insulin centralized procurement, achieving a procurement agreement volume of 46.86 million units, a 32.6% increase from the previous procurement [1] - The market share in the domestic market rose to the second position in the industry, only behind Novo Nordisk [1] International Market Performance - International revenue increased by 95 million yuan year-on-year, showing a growth of 75.08%, driven by the company's ongoing globalization strategy [2] - The company received approvals for its products in Malaysia, Pakistan, and Argentina, expanding its overseas market coverage [2] - The approval of the Gliclazide insulin PDP project in Brazil marks a significant milestone for local production capabilities in South America [2] Research and Development - The company invested 552 million yuan in R&D, accounting for 26.70% of its revenue [4] - The company is advancing in the fourth-generation insulin innovation track, with its self-developed GZR4 injection in global Phase III clinical trials [4] - The company is also actively entering the GLP-1 market, with its innovative GLP-1RA bi-weekly formulation, Bo Fang Ge Lu Tai, in Phase III clinical research [4] - The coverage of medical institutions has significantly increased, with 45,000 institutions covered, enhancing the company's leading position in the domestic insulin market [4]